<DOC>
	<DOCNO>NCT00851136</DOCNO>
	<brief_summary>This multicenter , open-label study enrol total 23 patient .</brief_summary>
	<brief_title>A Study PRO95780 Administered Combination With FOLFOX Regimen Bevacizumab Patients With Previously Untreated , Locally Advanced , Recurrent , Metastatic Colorectal Cancer ( APM4566g )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm CRC evidence locally advanced recurrent metastatic disease measurable tumor lesion Life expectancy &gt; 3 month For patient reproductive potential ( male female ) , use reliable mean contraception throughout trial 6 month follow final exposure study treatment Willingness capability accessible study followup Prior 5FU , capecitabine , and/or oxaliplatin treatment exception : prior oxaliplatin treatment≤ 6 week advance metastatic setting ; prior treatment 5FU , capecitabine , and/or oxaliplatin adjuvant set relapse occur &gt; 6 month conclude adjuvant therapy Peripheral neuropathy Grade ≥ 2 Prior radiotherapy measurable metastatic lesion ( ) use response assessment , unless lesion progress subsequent radiotherapy Radiotherapy peripheral lesion within 14 day prior Cycle 1 , Day 1 , radiotherapy thoracic , abdominal , pelvic field within 28 day prior Cycle 1 , Day 1 Chemotherapy , hormonal therapy , immunotherapy within 4 week prior Cycle 1 , Day 1 Evidence clinically detectable ascites Other invasive malignancy within 5 year prior Cycle 1 , Day 1 History evidence upon physical examination active central nervous system ( CNS ) disease Current recent participation another experimental drug study Clinically significant cardiovascular disease , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia within 1 year prior Cycle 1 , Day 1 , Grade II great peripheral vascular disease Active infection require parenteral antibiotic Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Cycle 1 , Day 1 , fine needle aspiration within 7 day prior Cycle 1 , Day 1 , anticipation need major surgical procedure course study Known suspect positive human immunodeficiency virus ( HIV ) Known positive hepatitis C hepatitis B surface antigen Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy History arterial thromboembolic event 6 month prior Cycle 1 , Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Cycle 1 , Day 1 Bleeding diathesis coagulopathy Pregnancy ( positive pregnancy test ) breast feed Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>CRC</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>APM4566g</keyword>
</DOC>